GlobeNewswire

YPO Welcomes 2018 YPO Innovation Week Sponsors

Dela

DALLAS, April 24, 2018 (GLOBE NEWSWIRE) -- YPO, the world's premier leadership organization of chief executives, announced today that Techstars has joined as a gold sponsor and Geniecast, Emplify and Telluride are silver sponsors of the 2018 YPO Innovation Week

YPO Innovation Week sponsors offer valuable insight, key connections and respected expertise that made the world's largest and most impactful innovation initiative possible.

"YPO Innovation Week brings together some of the most innovative and disruptive leaders around the world," said YPO CEO Scott Mordell. "We are so pleased to partner with these prestigious and forward-thinking organizations and businesses to help elevate the week's experiences for our members and take innovation to the next level."

During the week of 7-11 May 2018, YPO will host innovation events across the globe from Sydney, Australia to London, England; Tel Aviv, Israel to New York, New York, USA; Santo Domingo, Dominican Republic to Palo Alto, California, USA and Nairobi, Kenya, and more.

The mission of YPO Innovation Week is to drive innovation and transformation across a diverse range of industries and sectors through signature events, live interactive video casts and livestream events across more than 30 countries. Business leaders and pioneering thinkers will engage in a weeklong forum discussing the most important innovations affecting business today, including augmented and virtual reality, vehicle technology, digital imaging, wearables, smart home, sensors and more.

"We welcome these prestigious partners and their participation in the 2018 YPO Innovation Week," said YPO Innovation Week Chair Keith Alper. "With their support, we will truly be able to overturn conventional thinking and inspire business leaders to accelerate what's next."

Gold Sponsors
Techstars is featuring Techstars Founders who will deliver pitches at several YPO Innovation Week events, including the Global FinTech Summit, the World Technology Summit and the NYSE Closing Bell event.

Silver Sponsors
Geniecast is hosting digital events throughout YPO Innovation Week via two-way video broadcast.

Emplify's CEO Santiago Jaramillo, a YPO member, will present on the future of work at the Silicon Valley Summit and World Technology Summit.

Telluride is hosting a virtual reality space at the Silicon Valley Summit and providing an exclusive prize package for YPO Global Innovation Award finalists.

About YPO 

The premier leadership organization of chief executives in the world.

YPO is the global platform for chief executives to engage, learn and grow. YPO members harness the knowledge, influence and trust of the world's most influential and innovative business leaders to inspire business, personal, family and community impact.

Today, YPO empowers more than 25,000 members in more than 130 countries, diversified among industries and types of businesses. Altogether, YPO member-run companies employ more than 16 million people and generate USD6 trillion in annual revenues.

Leadership. Learning. Lifelong. For more information, visit YPO.org.

About Techstars
Techstars is the worldwide network that helps entrepreneurs succeed. Techstars founders connect with other entrepreneurs, experts, mentors, alumni, investors, community leaders, and corporations to grow their companies. Techstars operates four divisions: Techstars Startup Programs, Techstars Mentorship-Driven Accelerator Programs, Techstars Corporate Innovation Partnerships, and the Techstars Venture Capital Fund. Techstars portfolio includes more than 1,300 companies with a market cap of $12 billion. www.techstars.com

About Geniecast
Geniecast is transforming the way the world connects people, ideas, and inspiration. We are curators, producers, and distributors of the world's largest online marketplace of thought leaders, athletes, speakers, celebrities, facilitators and more - all available via two-way, live video broadcast. Join us in the quest to inspire, lead, and evolve. At Geniecast, we strive to offer human-centric client services through great people and clever technology, one transaction at a time. From a warm welcome to individualized attention, we engage with you, one connection at a time. And, when you least expect it, we plan to surprise you with an extra touch, one experience at a time. To learn more, visit https://geniecast.com/.

About Emplify
Emplify, the industry leader in data-driven employee analytics and action-enabling insights for business leaders, helps executives leverage employee insights to make their workforce more successful. Backed by decades of research in human psychology and neuroscience, Emplify InsightsTM blends employee engagement best practices and hands-on expert coaching into an agile feedback system that's simple yet more effective than historic annual employee surveys, and more trustworthy than modern pulse surveys. Emplify is trusted by companies like Ivy Tech Community College, Herff Jones, Harley Davidson, Cheetah Digital, Crew Carwash, Yamaha, and many others. Learn more at emplify.com.

About Telluride
Forty-five minutes from the nearest stoplight, at the end of a incredibly beautiful box canyon sits Telluride, Colorado, a National Historic Landmark surrounded by the highest concentration of 13,000' and 14,000' peaks in the United States. Above Telluride is a modern mountain village connected by a gondola, the only one of its kind in North America. While the ski terrain is world-renowned, the resort is truly defined by a collection of intimate and unmatched experiences. With your first walk down the historic main street, you'll find the character and charm of Telluride as special as the majestic San Juan Mountains. To learn more, visit www.tellurideskiresort.com .

Contact:
YPO
Linda Fisk
Office: +1 972 629 7305 (United States)
Mobile: +1 972 207 4298 
press@ypo.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: YPO via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62197.3.2019 09:00:00 CETPressmeddelande

STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis. The results found FOR 6219 to be safe and well tolerated, with good pharmacokinetics at the doses tested. The randomized, double blind, placebo controlled Phase Ia study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR 6219 in 36 healthy postmenopausal women. In the study, single doses of FOR 6219 from 2 mg up to 175 mg and multiple doses up to 150 mg twice daily for ten days were found to be safe and well tolerated. The pharmacokinetic results showed a dose proportionate exposure and no significant food effect. The safety and pharmacokinetic profile of FOR 6219 supports the initiation of a Phase Ib clinical trial in healthy premenopausal women with the aim to demonstrate Proof of Mechanism. The selective abi

Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62197.3.2019 09:00:00 CETPressmeddelande

STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis. The results found FOR 6219 to be safe and well tolerated, with good pharmacokinetics at the doses tested. The randomized, double blind, placebo controlled Phase Ia study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR 6219 in 36 healthy postmenopausal women. In the study, single doses of FOR 6219 from 2 mg up to 175 mg and multiple doses up to 150 mg twice daily for ten days were found to be safe and well tolerated. The pharmacokinetic results showed a dose proportionate exposure and no significant food effect. The safety and pharmacokinetic profile of FOR 6219 supports the initiation of a Phase Ib clinical trial in healthy premenopausal women with the aim to demonstrate Proof of Mechanism. The selective abi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum